The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC

Video content above is prompted by the following:

Treatment Sequencing and One-Line Disease Course

Key Themes:

• Sequential Treatment Planning: Importance of first-line treatment selection given many patients never receive second-line therapy
• Cross-Trial Comparisons: Differences between MARIPOSA and FLAURA2 affecting interpretation and sequencing strategy
• Transition Points: Challenges in ensuring patients remain eligible for subsequent therapy at progression

Notable Insights:

• Dr Piotrowska: Noted that “in some studies up to 40% or so of patients never make it to a second-line therapy,” emphasizing the critical importance of first-line regimen selection.
• Dr Dietrich: Described transition points as “very sobering” and emphasized the need for oncologist involvement when patients progress, noting “with a 71% attrition rate in MARIPOSA, we’re still losing almost 30% of patients” before second-line therapy.